Related references
Note: Only part of the references are listed.Slow-Onset Inhibition of the Fabl Enoyl Reductase from Francisella tularensis: Residence Time and in Vivo Activity
Hao Lu et al.
ACS CHEMICAL BIOLOGY (2009)
Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior
Ravi Rajagopalan et al.
BIOCHEMISTRY (2009)
Molecular mechanisms for the persistent bronchodilatory effect of the beta(2)-adrenoceptor agonist salmeterol
A. Szczuka et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations
Johan Gabrielsson et al.
DRUG DISCOVERY TODAY (2009)
Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
Bart A. Ploeger et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process
U. Helena Danielson
FUTURE MEDICINAL CHEMISTRY (2009)
Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: Application to (R)-dimethindene occupancy of central histamine H1 receptors
Siobhan Malany et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2009)
The role of dynamic conformational ensembles in biomolecular recognition
David D. Boehr et al.
NATURE CHEMICAL BIOLOGY (2009)
Do molecularly targeted agents in oncology have reduced attrition rates?
Ian Walker et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Selected-fit versus induced-fit protein binding: Kinetic differences and mutational analysis
Thomas R. Weikl et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2009)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Novel P2Y(12) adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets
Judi Bryant et al.
THROMBOSIS RESEARCH (2008)
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier
Inge Dierynck et al.
JOURNAL OF VIROLOGY (2007)
Neurokinin 1 receptor antagonists:: Correlation between in vitro receptor interaction and in vivo efficacy
Erik Lindstroem et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism
Trudy A. Kohout et al.
MOLECULAR PHARMACOLOGY (2007)
Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes
Kang Yan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Slow antagonist dissociation and long-lasting in vivo receptor protection
Georges Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans
Georges Vauquelin et al.
JOURNAL OF HYPERTENSION (2006)
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
RB Perni et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase
A Lewandowicz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Optical biosensors in drug discovery
MA Cooper
NATURE REVIEWS DRUG DISCOVERY (2002)
Share Paper
